Paper Details

  1. Home
  2. Paper Details

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.

Author: AkilovOleg E, BechterOliver, BunnVeronica, DalleStephane, DummerReinhard, DuvicMadeleine, EradatHerbert, FisherDavid C, GeskinLarisa, HorwitzSteven M, KimYoun H, LisanoJulie, LittleMeredith, Ortiz-RomeroPablo L, Pinter-BrownLauren, PrinceH Miles, QuaglinoPietro, SanchesJose A, ScarisbrickJulia J, StadlerRudolf, TaylorKerry, TrotmanJudith, WalewskiJan, WeichenthalMichael, WhittakerSean, ZinzaniPier Luigi

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study reports final data from the phase 3 ALCANZA trial, demonstrating significantly improved objective responses and progression-free survival with brentuximab vedotin compared to physician's choice in CD30-expressing mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (C-ALCL).
Paper Details　
Original Abstract of the Article :
The primary analysis of the phase 3 ALCANZA trial showed significantly improved objective responses lasting ≥4 months (ORR4; primary endpoint) and progression-free survival (PFS) with brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in CD30-expressing mycosis fungoides (MF) or ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153035/

データ提供：米国国立医学図書館（NLM）

Brentuximab Vedotin: A Shining Light in Cutaneous T-Cell Lymphoma Treatment

The treatment of [cutaneous T-cell lymphoma (CTCL)] remains a challenge for healthcare professionals. This study, like a dedicated physician navigating a complex medical landscape, evaluates the efficacy of brentuximab vedotin in treating CD30-expressing CTCL.

The researchers, meticulously analyzing data from a phase 3 clinical trial, discovered that brentuximab vedotin significantly improved objective responses and progression-free survival compared to physician's choice treatment in patients with CD30-expressing mycosis fungoides (MF) or primary cutaneous anaplastic large-cell lymphoma (C-ALCL). This discovery, like a well-stocked oasis in a parched desert, offers a promising treatment option for patients with these forms of CTCL.

Furthermore, the study highlighted the ability of brentuximab vedotin to improve skin symptom burden, including pruritus and pain, without negatively impacting quality of life. This finding, like a cool breeze in the desert, underscores the importance of considering both clinical efficacy and patient well-being in treatment decisions.

A New Era in CTCL Treatment: The Power of Brentuximab Vedotin

This study, like a groundbreaking scientific discovery, demonstrates the potential of brentuximab vedotin to transform the treatment of CD30-expressing CTCL. This research, like a beacon illuminating the path forward, offers hope for patients seeking effective and tolerable treatments for these challenging conditions.

A Journey Towards Better Outcomes: Embracing Innovative Treatments for CTCL

The study reinforces the importance of ongoing research and innovation in the field of CTCL treatment. This ongoing journey, like a caravan traversing a vast desert, seeks to improve the lives of patients by developing safer and more effective therapies.

Dr.Camel's Conclusion

This study, like a well-traveled road through a vast desert, highlights the potential of brentuximab vedotin to improve the lives of patients with CD30-expressing CTCL. By embracing innovative treatments and continuing to seek new solutions, we can hope for a future where patients with these challenging conditions can experience improved outcomes and a better quality of life.

Date :
  1. Date Completed 2022-01-06
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

34507350

DOI: Digital Object Identifier

PMC9153035

Related Literature

Article Analysis
・Effects of bexarotene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.